Real-World Outcomes of the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema. [PDF]
Morozova C +7 more
europepmc +1 more source
Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy. [PDF]
Lima-Fontes M +7 more
europepmc +1 more source
The effectiveness of the 0.19 mg fluocinolone acetonide implant in treating non-infectious posterior uveitis: a real-world experience. [PDF]
Kozak I, Gurbaxani A, Pandova M.
europepmc +1 more source
Fluocinolone Acetonide Implant for Uveitis: Dissecting Responder and Non-Responder Outcomes at a Tertiary Center. [PDF]
Abu Arif J +7 more
europepmc +1 more source
Correction: Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations. [PDF]
Pleyer U +9 more
europepmc +1 more source
Fluocinolone acetonide 0.18-mg implant for treatment of recurrent inflammation due to non-infectious uveitis: a case series of 15 patients. [PDF]
Sisk RA +5 more
europepmc +1 more source
SUSTAINED-RELEASE LOW-DOSE FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT FOR CHRONIC POSTOPERATIVE CYSTOID MACULAR EDEMA: TWO CASE REPORTS. [PDF]
Kiernan DF.
europepmc +1 more source
Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network. [PDF]
Jabbour M +12 more
europepmc +1 more source
Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations. [PDF]
Pleyer U +9 more
europepmc +1 more source

